BRPI1013877A2 - Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r - Google Patents
Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6rInfo
- Publication number
- BRPI1013877A2 BRPI1013877A2 BRPI1013877A BRPI1013877A BRPI1013877A2 BR PI1013877 A2 BRPI1013877 A2 BR PI1013877A2 BR PI1013877 A BRPI1013877 A BR PI1013877A BR PI1013877 A BRPI1013877 A BR PI1013877A BR PI1013877 A2 BRPI1013877 A2 BR PI1013877A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino acid
- polypeptides
- sequences
- disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
SEQUÊNCIAS DE AMINOÁCIDOS MELHORADAS CONTRA IL-6R E POLIPEPTÍDEOS QUE COMPREENDEM OS MESMOS PARA O TRATAMENTO DE DOENÇAS E DISTÚRBIOS RELACIONADOS COM IL-6R. A presente invenção se refere às sequências de aminoácidos que são direcionadas contra e/ou que podem se ligar especificamente ao receptor de interleucina-6 (IL-6R) com afinidade e/ou avidez melhorada, e/ou que têm uma maior eficácia e/ou potência, e que são capazes de (parcialmente ou de preferência totalmente) bloquear a interação de IL-6/IL-6R e/ou inibir a sinalização através de IL-6, IL-6R e/ou do complexo IL6/IL-6R. A invenção também se relaciona aos compostos ou construtos, e especialmente às proteínas e polipeptídeos que compreendem ou essencialmente consistem em uma ou mais sequências de aminoácidos. A invenção também se refere aos ácidos nucléicos que codificam tais sequências de aminoácidos e polipeptídeos, aos métodos para preparar tais sequências de aminoácidos e polipeptídeos, as células hospedeiras que expressam ou são capazes de expressar tais sequências de aminoácidos ou polipeptídeos, as composições e, em particular as composições farmacêuticas, que compõem tais sequências de aminoácidos, polipeptídeos, ácidos nucléicos e/ou células hospedeiras, e ao uso de tais sequências de aminoácidos ou polipeptídeos, ácidos nucléicos, células hospedeiras e/ou composições, em particular para fins profiláticos, terapêuticos ou de diagnósticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16841009P | 2009-04-10 | 2009-04-10 | |
PCT/EP2010/054764 WO2010115998A2 (en) | 2009-04-10 | 2010-04-12 | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1013877A2 true BRPI1013877A2 (pt) | 2017-08-15 |
Family
ID=42199717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1013877A BRPI1013877A2 (pt) | 2009-04-10 | 2010-04-12 | Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r |
Country Status (16)
Country | Link |
---|---|
US (5) | US8748581B2 (pt) |
EP (2) | EP3461844A3 (pt) |
JP (2) | JP5647222B2 (pt) |
KR (2) | KR101470690B1 (pt) |
CN (2) | CN102388069B (pt) |
AU (1) | AU2010233658B2 (pt) |
BR (1) | BRPI1013877A2 (pt) |
CA (1) | CA2758191C (pt) |
HK (1) | HK1222863A1 (pt) |
IL (2) | IL215525B (pt) |
MX (1) | MX2011010681A (pt) |
NZ (1) | NZ595461A (pt) |
RU (1) | RU2539798C2 (pt) |
SG (1) | SG174862A1 (pt) |
WO (1) | WO2010115998A2 (pt) |
ZA (1) | ZA201107055B (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
MX2011010681A (es) * | 2009-04-10 | 2012-01-20 | Ablynx Nv | Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r. |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US20130261288A1 (en) | 2010-10-29 | 2013-10-03 | Ablynx N.V. | Method for the production of immunoglobulin single variable domains |
CN108653728B (zh) * | 2011-06-23 | 2022-11-18 | 埃博灵克斯股份有限公司 | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 |
AU2012275287B2 (en) | 2011-06-28 | 2017-10-05 | Inhibrx, Inc. | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
EP2987806A3 (en) * | 2011-08-17 | 2016-07-13 | Glaxo Group Limited | Modified single variable domain antibodies with reduced binding to anti-drug-antibodies |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
US10105418B2 (en) * | 2013-12-23 | 2018-10-23 | Staley A. Brod | Oral administration of tocilizumab treatment of autoimmune disease |
JP6636498B2 (ja) * | 2014-03-21 | 2020-01-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 単一ドメイン結合タンパク質を作る非ヒト動物 |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
CA2963712A1 (en) * | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
CN105342216B (zh) * | 2015-09-25 | 2019-01-04 | 国网山东商河县供电公司 | 一种告知书收纳取用装置 |
NO2768984T3 (pt) | 2015-11-12 | 2018-06-09 | ||
WO2017125578A1 (en) * | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
JP2019523213A (ja) | 2016-05-02 | 2019-08-22 | アブリンクス エン.ヴェー. | Rsv感染の処置 |
WO2018007442A1 (en) | 2016-07-06 | 2018-01-11 | Ablynx N.V. | Treatment of il-6r related diseases |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
WO2018029182A1 (en) | 2016-08-08 | 2018-02-15 | Ablynx N.V. | Il-6r single variable domain antibodies for treatment of il-6r related diseases |
WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
CN117700549A (zh) | 2016-11-16 | 2024-03-15 | 埃博灵克斯股份有限公司 | 能够结合CD123和TCRα/β的T细胞募集多肽 |
JP7001615B2 (ja) | 2016-11-28 | 2022-02-03 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
WO2018111099A1 (en) | 2016-12-12 | 2018-06-21 | Stichting Vumc | Biomarkers and treatments for cerebral amyloid angiopathy (caa) |
WO2018111325A1 (en) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Methods and ingestible devices for the regio-specific release of il-6r inhibitors at the site of gastrointestinal tract disease |
UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
JP7249961B2 (ja) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adamts5、mmp13およびアグリカンに結合するポリペプチド |
KR20200015601A (ko) | 2017-06-02 | 2020-02-12 | 메르크 파텐트 게엠베하 | Mmp13 결합성 면역글로불린 |
SG10202113337YA (en) | 2017-06-02 | 2021-12-30 | Ablynx Nv | Aggrecan binding immunoglobulins |
EP4272822A3 (en) | 2017-06-02 | 2024-03-27 | Merck Patent GmbH | Adamts binding immunoglobulins |
TW201936208A (zh) | 2017-11-28 | 2019-09-16 | 日商中外製藥股份有限公司 | 含有抗原結合域及運輸部分之多胜肽 |
US20220106398A1 (en) * | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
WO2020254827A1 (en) * | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
CN114514243A (zh) | 2019-06-21 | 2022-05-17 | 索瑞索制药公司 | 多肽 |
CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
CA3201219A1 (en) | 2020-12-04 | 2022-06-09 | Mir Ali | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
CN112778416B (zh) * | 2020-12-30 | 2022-02-22 | 康元医疗科技(大连)有限公司 | 一种纳米抗体、涉及该纳米抗体的多肽及其应用 |
US20240002331A1 (en) | 2022-06-08 | 2024-01-04 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
EP0257406B2 (en) | 1986-08-06 | 1998-08-12 | Ajinomoto Co., Inc. | Recombinant B-cell differentiation factor |
US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
JP2598666B2 (ja) | 1987-10-19 | 1997-04-09 | 忠三 岸本 | 抗ヒトbcdfモノクローナル抗体 |
CA1341152C (en) | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
CA2001774C (en) | 1988-10-28 | 2001-10-16 | James A. Wells | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
ATE144713T1 (de) | 1989-07-20 | 1996-11-15 | Tadamitsu Kishimoto | Antikörper gegen menschlichen interleukin-6- rezeptor |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
JP2898064B2 (ja) | 1989-08-03 | 1999-05-31 | 忠三 岸本 | ヒトgp130蛋白質 |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
JP4251406B2 (ja) | 1990-04-05 | 2009-04-08 | クレア,ロベルト | ウォーク―スルー突然変異誘発 |
DE69229482T2 (de) | 1991-04-25 | 1999-11-18 | Chugai Pharmaceutical Co Ltd | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
JPH05304986A (ja) | 1992-04-28 | 1993-11-19 | Tosoh Corp | gp130蛋白質に対するモノクロ−ナル抗体 |
AU687010B2 (en) | 1992-07-17 | 1998-02-19 | Dana-Farber Cancer Institute | Method of intracellular binding of target molecules |
DK1621554T4 (da) | 1992-08-21 | 2012-12-17 | Univ Bruxelles | Immunoglobuliner blottet for lette kæder |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
DK0702721T3 (da) | 1993-06-09 | 2001-05-21 | Unilever Nv | Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
CA2169298A1 (en) | 1993-09-10 | 1995-03-16 | Martin Chalfie | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
EP0745134A1 (en) | 1994-02-22 | 1996-12-04 | Danafarber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
CN100350973C (zh) * | 1994-10-21 | 2007-11-28 | 岸本忠三 | 用于治疗il-6产生所致疾病的药物组合物 |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
JP4540132B2 (ja) | 1995-02-13 | 2010-09-08 | 中外製薬株式会社 | Il−6レセプター抗体を含んでなる筋蛋白分解抑制剤 |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
EP0833907A1 (en) | 1995-06-23 | 1998-04-08 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
AU4482996A (en) | 1995-09-22 | 1997-04-09 | Novo Nordisk A/S | Novel variants of green fluorescent protein, gfp |
DK0852587T3 (da) | 1995-09-28 | 2009-06-08 | Yeda Res & Dev | Syntetiske peptider der inhiberer IL-6-aktivitet |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
EP1027073A2 (en) | 1996-11-19 | 2000-08-16 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
FR2766826B1 (fr) | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
JP2003525016A (ja) | 1998-02-19 | 2003-08-26 | エクサイト セラピーズ, インコーポレイテッド | リンパ球活性化を調節するための組成物および方法 |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
WO2000046383A2 (en) | 1999-02-05 | 2000-08-10 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
AU784108B2 (en) | 1999-03-15 | 2006-02-02 | University Of British Columbia, The | Methods and reagents for modulating cholesterol levels |
CA2375787C (en) | 1999-06-18 | 2007-03-27 | Cv Therapeutics, Inc. | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
AU6322900A (en) | 1999-08-02 | 2001-02-19 | Keygene N.V. | Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method |
AU7078200A (en) | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
CN1268394C (zh) | 2001-01-17 | 2006-08-09 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1425694A2 (en) | 2001-08-03 | 2004-06-09 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
FR2829940A1 (fr) | 2001-09-27 | 2003-03-28 | Synt Em | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central |
DK1562968T3 (da) * | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
SI1517921T1 (sl) | 2002-06-28 | 2006-10-31 | Domantis Ltd | Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
AU2003284891A1 (en) | 2002-10-23 | 2004-05-13 | Ludwig Institute For Cancer Research | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
CA2505326A1 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
JP4791960B2 (ja) | 2003-06-27 | 2011-10-12 | バイオレン,インク. | ルックスルー突然変異誘発 |
AU2004220325B2 (en) | 2003-06-30 | 2011-05-12 | Domantis Limited | Polypeptides |
US7539903B2 (en) | 2003-06-30 | 2009-05-26 | Siemens Aktiengesellschaft | Method for monitoring the execution of a program by comparing a request with a response and introducing a falsification in a response |
CA2535550A1 (en) | 2003-08-12 | 2005-03-03 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
EP1512696A1 (en) | 2003-08-14 | 2005-03-09 | Diatos | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
US7207410B2 (en) | 2004-04-29 | 2007-04-24 | Daimlerchrysler Corporation | Apparatus and method for enhanced impact sensing |
WO2006023144A2 (en) | 2004-07-06 | 2006-03-02 | Bioren Inc. | Look-through mutagenesis for developing altered polypeptides with enhanced properties |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
MX2007014359A (es) | 2005-05-18 | 2008-02-06 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
CN101321784A (zh) * | 2005-10-11 | 2008-12-10 | 埃博灵克斯股份有限公司 | 针对egfr和igf-ir的纳米抗体tm和多肽 |
CA2644405A1 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
JP2010502208A (ja) * | 2006-09-08 | 2010-01-28 | アブリンクス エン.ヴェー. | 半減期の長い血清アルブミン結合タンパク質 |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
ATE536369T1 (de) | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
WO2008068280A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
JP2010512734A (ja) | 2006-12-13 | 2010-04-30 | アブリンクス エン.ヴェー. | Il−6/il−6受容体複合体等受容体介在性シグナル伝達に関与する複合体に特異的なポリペプチド |
WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
US8906680B2 (en) | 2006-12-22 | 2014-12-09 | Ablynx N.V. | Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders |
AU2008270274B2 (en) * | 2007-07-03 | 2012-06-28 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating CDR and/or FR positions |
WO2009010539A2 (en) | 2007-07-19 | 2009-01-22 | Ablynx. N.V. | Receptor for interleukin-6 (il-6) from macaca fascicularis |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
US20110243954A1 (en) * | 2008-04-17 | 2011-10-06 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
EP2403873A1 (en) * | 2009-03-05 | 2012-01-11 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
US10618964B2 (en) | 2009-04-10 | 2020-04-14 | Ablynx N.V. | Nanobody against IL-6R |
MX2011010681A (es) | 2009-04-10 | 2012-01-20 | Ablynx Nv | Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r. |
PT2473528E (pt) * | 2009-09-03 | 2015-03-04 | Ablynx Nv | Formulações estáveis de polipéptidos e seus usos |
US20130012916A1 (en) | 2010-02-11 | 2013-01-10 | Glide Pharmaceutical Technologies Limited | Delivery of immunoglobulin variable domains and constructs thereof |
TWI603738B (zh) | 2010-11-08 | 2017-11-01 | 建南德克公司 | 皮下投予抗-il-6受體抗體 |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
-
2010
- 2010-04-12 MX MX2011010681A patent/MX2011010681A/es active IP Right Grant
- 2010-04-12 BR BRPI1013877A patent/BRPI1013877A2/pt not_active IP Right Cessation
- 2010-04-12 EP EP18202818.3A patent/EP3461844A3/en not_active Withdrawn
- 2010-04-12 NZ NZ595461A patent/NZ595461A/xx not_active IP Right Cessation
- 2010-04-12 AU AU2010233658A patent/AU2010233658B2/en not_active Ceased
- 2010-04-12 CN CN201080016107.5A patent/CN102388069B/zh not_active Expired - Fee Related
- 2010-04-12 JP JP2012504035A patent/JP5647222B2/ja not_active Expired - Fee Related
- 2010-04-12 SG SG2011066776A patent/SG174862A1/en unknown
- 2010-04-12 CA CA2758191A patent/CA2758191C/en not_active Expired - Fee Related
- 2010-04-12 KR KR1020117026718A patent/KR101470690B1/ko active IP Right Grant
- 2010-04-12 US US13/263,179 patent/US8748581B2/en active Active
- 2010-04-12 RU RU2011145567/10A patent/RU2539798C2/ru active
- 2010-04-12 CN CN201510266599.8A patent/CN105399828B/zh not_active Expired - Fee Related
- 2010-04-12 WO PCT/EP2010/054764 patent/WO2010115998A2/en active Application Filing
- 2010-04-12 EP EP10714242.4A patent/EP2417163B1/en not_active Not-in-force
- 2010-04-12 KR KR1020137025878A patent/KR20130119990A/ko not_active Application Discontinuation
-
2011
- 2011-09-27 ZA ZA2011/07055A patent/ZA201107055B/en unknown
- 2011-10-04 IL IL215525A patent/IL215525B/en not_active IP Right Cessation
-
2014
- 2014-03-21 US US14/221,364 patent/US8962805B2/en active Active
- 2014-03-21 US US14/221,409 patent/US9273150B2/en active Active
- 2014-03-21 US US14/221,389 patent/US9181350B2/en active Active
- 2014-06-03 JP JP2014115308A patent/JP6159684B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-12 US US15/042,316 patent/US10392440B2/en active Active
- 2016-09-16 HK HK16110949.3A patent/HK1222863A1/zh unknown
-
2017
- 2017-04-25 IL IL251916A patent/IL251916A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1013877A2 (pt) | Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
PH12017501583A1 (en) | Novel proteins specific for cd137 | |
MX2010005783A (es) | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. | |
EA201190326A1 (ru) | Полипептиды гормона роста и способы их получения и применения | |
CA2818969A1 (en) | Improved n-terminal capping modules for designed ankyrin repeat proteins | |
EA201270528A1 (ru) | Композиции цитокинов семейства il-17 и их применение | |
MX2009012650A (es) | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. | |
PH12016500239A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
EA201491644A1 (ru) | Фармацевтические композиции | |
BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
WO2011028344A3 (en) | Interleukin-1 receptor antagonist compositions and methods of making and using same | |
MY162737A (en) | 4-1bb binding molecules | |
BR112012029588A2 (pt) | materiais biológicas relacionados a her3. | |
MX352205B (es) | Sistemas de expresion. | |
AR072000A1 (es) | Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma | |
WO2009095489A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
MX2016017308A (es) | Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades. | |
TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
BR112017020961A2 (pt) | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação | |
MY156337A (en) | Agonist dr5 binding polypeptides | |
MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |